Wellcome letter


Hi to all of our followers! First of all I have to thank all of you for letting me take care of your health and lifestyle. Hopefully you have found some answers to your problems and are well on your way to a healthier you or hopefully you are already on a maintenance plan facing your relationship with food and the scale in a new amicable way. As I probably commented before, I am starting a new way of anonymous communication with all of you. There is a lot of information to be shared as well as a lot of experience and tips that can benefit most of us. As all of you know, I insist and always recommend to be part of a support group, one of the keys to success and one of the main pillars of Lifestyle Intervention for Weight Loss. You also know that I can not share individual information. This blog will be a way of having that. I invite you all to participate and post your experience without sharing any of your personal information. My second intention is to share as much medical/nutritional information as I can. The more educated you become the easier it will be to understand what you are going through.



Link: http://www.lifestylemedicinespecialists.com/







Tuesday, July 24, 2012

New drugs not yet available

Lorcaserin
Lorcaserin/BelviQ
In June 2012, the US Food and Drug Administration approved our internally discovered and developed drug, BELVIQ® (lorcaserin HCI).
We are also seeking regulatory approval for lorcaserin in the European Union, and intend to seek regulatory approval for lorcaserin in additional territories. Regulatory agencies outside the US will independently review lorcaserin.
Our wholly owned subsidiary, Arena Pharmaceuticals GmbH has granted Eisai Inc. exclusive rights to commercialize lorcaserin in most of North and South America, including the United States, Canada, Mexico and Brazil, subject to applicable regulatory approval.
We have patents or patent applications that cover lorcaserin in the United States, Europe, Canada, Mexico, Brazil and many other jurisdictions that, if issued, in most cases would be capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity we might obtain.
BELVIQ will not be available for sale in the United States until after the Drug Enforcement Administration of the US Department of Justice determines BELVIQ’s final scheduling designation.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)